CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 22, 2021
Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intradermal microneedle patch, announced it was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH). Vaxess will receive up to $2.85 million over the course of the award if the project milestones are met.
The CRP grant will be used to advance the commercialization of the MIMIX technology via CMC activities including design and quality control systems, clinical lot manufacturing, and continued engagement with regulatory stakeholders in preparation for a Phase I clinical trial. This first human trial of a MIMIX product will test a seasonal flu and a COVID-19 vaccine under an FDA IND projected to be filed within a year.
J&J COVID-19 vaccine pause under review as U.S. advisers weigh clot reports
The vaccine was paused by the CDC and U.S. Food and Drug Administration last week after reports of rare but serious blood clots associated with low blood platelets. Top health officials have said they hope for a return to the vaccine s use after the panel meets.
Written By:
Manas Mishra and Julie Steenhuysen / Reuters | 12:35 pm, Apr. 23, 2021 ×
A vial and sryinge are seen in front of a displayed Johnson & Johnson logo in this illustration taken Jan. 11, 2021. (REUTERS/Dado Ruvic/Illustration/File Photo)
April 23 (Reuters) - Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Friday are considering if it is safe to resume injections of Johnson & Johnson s COVID-19 vaccine, even as senior U.S. health officials prepare for a green light.
demand of essential treatment supplies like oxygen
, medicines, ventilator and beds.
And interestingly, the Remdesivir drug has also become a sought after item this time
, in spite of the World Health Organisation recommending against its use time and again.
The World Health Organization (WHO) has clearly said that there is still no evidence to indicate that Remdesivir is beneficial in treating hospitalised coronavirus patients.
Earlier in April, WHO’s chief scientist Dr. Soumya Swaminathan and its Technical Lead on COVID, Dr. Maria Van Kerkhove, told
India Today TV that findings from five clinical trials in the past show that the use of the antiviral drug has not helped in curtailing mortality or reducing the need for mechanical ventilation among hospitalised COVID-19 patients.
Article content
The United States can immediately resume use of Johnson & Johnson’s COVID-19 vaccine, top health regulators said on Friday, ending a 10-day pause to investigate its link to extremely rare but potentially deadly blood clots.
The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration said the risks of experiencing the syndrome involving severe blood clots and low platelets as a result of the vaccine was very low. They found 15 cases in the 8 million shots given.
We apologize, but this video has failed to load.
Try refreshing your browser, or U.S. CDC to resume use of J&J vaccines after health officials investigate cases of blood clots Back to video